Back to All Combinations

MUTYH Polyposis

Intermediate Prognosis
0.30% Prevalence Level 2A Special Populations
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
MUTYH
Treatment Implications

Autosomal recessive. Biallelic mutations needed.

Recommended Treatments
Surgery
Surveillance
Family testing
Treatments to Avoid

No specific contraindications noted

Study References

NCCN Genetic

Key Statistics
0.30%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Recessive inheritance pattern.
Information

Category: Special Populations

Evidence Level: Level 2A

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.